16 unknown, 7 recruiting, 5 completed, 2 not yet recruiting. 4 Phase 1, 4 Phase 2, 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Unknown 2 |
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Not applicable | 3 | Unknown 2, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Geneplus-Beijing Co. Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Timing of ctDNA Testing in Advanced Breast Cancer Advanced Breast Cancer | Recruiting | Geneplus-Beijing Co. Ltd. | 400 | 2026-07-08 | 2026-09-15 | |
| Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD Standard Therapy, Adaptive Therapy - NSCLC | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 286 | 2025-04-06 | 2025-10-02 |
| Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer Breast Cancer Screening | Recruiting | Geneplus-Beijing Co. Ltd. | 200 | 2025-03-15 | 2025-03-14 | |
| The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer Ovarian Cancer | Not yet recruiting | Geneplus-Beijing Co. Ltd. | 80 | 2024-12-01 | 2024-07-18 | |
| Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer MRD-ctDNA - Endometrial Cancer | Not applicable | Unknown | The First Hospital of Jilin University | 100 | 2024-01-25 | 2024-04-02 |
| Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable | Phase 2 | Unknown | Tongji Hospital | 36 | 2023-12-09 | 2024-01-09 |
| Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients Colorectal Cancer | Recruiting | Geneplus-Beijing Co. Ltd. | 60 | 2023-10-30 | 2026-06-30 | |
| Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq) Whole-genome Methylation Sequencing(GM-seq) - Pulmonary Nodule, Solitary, Whole-genome Methylation Sequencing | Completed | Geneplus-Beijing Co. Ltd. | 158 | 2023-07-01 | 2025-09-04 | |
| Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Lung Cancer | Recruiting | Geneplus-Beijing Co. Ltd. | 100 | 2023-06-19 | 2026-06-30 | |
| ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy NGS and ctDNA-MRD detection - Non-small Cell Lung Cancer | Not yet recruiting | Second Xiangya Hospital of Central South University | 50 | 2023-04-01 | 2023-04-20 | |
| Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer NSCLC | Unknown | Peking University Cancer Hospital & Institute | 65 | 2022-11-25 | 2023-10-13 | |
| Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemotherapy, Lenvatinib - Hepatocellular Carcinoma | Phase 1 | Unknown | Wan-Guang Zhang | 30 | 2022-09-01 | 2023-12-19 |
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1 - Cholangiocarcinoma Non-resectable | Unknown | Ze-yang Ding, MD | 100 | 2022-02-01 | 2024-01-09 | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma TACE, Lenvatinib, Anti-PD-1 monoclonal antibody - Hepatocellular Carcinoma Non-resectable | Unknown | Tongji Hospital | 300 | 2022-01-20 | 2024-06-13 | |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer Observation - Primary Liver Cancer, Hepatocellular Carcinoma | Withdrawn | Geneplus-Beijing Co. Ltd. | 2021-12-20 | 2024-02-23 | ||
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy Immune Checkpoint Inhibitors - Biliary Tract Cancer, Immune Checkpoint Inhibitor | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 50 | 2021-12-01 | 2024-02-08 |
| Hepatobiliary Tumors Tissue Samples Acquisition Gene expression analysis, Genomic analysis, Protein expression analysis - Hepatocellular Carcinoma, Cholangiocarcinoma | Unknown | Peking Union Medical College Hospital | 450 | 2020-10-11 | 2023-07-07 | |
| Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients Observation - Lung Neoplasms, Lung Cancer, Nonsmall Cell | Completed | Geneplus-Beijing Co. Ltd. | 252 | 2020-07-01 | 2026-06-29 | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab - Hepatocellular Carcinoma Non-resectable | Recruiting | Ze-yang Ding, MD | 300 | 2020-05-19 | 2025-03-25 | |
| Primary Hepatobiliary Cancer Cohort of Central China Hepatocellular Carcinoma, Biliary Tract Neoplasms | Unknown | Tongji Hospital | 2000 | 2020-05-01 | 2023-12-19 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Hepatocellular (6) · Carcinoma, Non-Small-Cell Lung (6) · Lung Neoplasms (6) · Cholangiocarcinoma (4) · Adenocarcinoma of Lung (3) · Biliary Tract Neoplasms (3) · Liver Neoplasms (2) · Ovarian Neoplasms (2) · Rectal Neoplasms (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Neoplasms (1) · Precancerous Conditions (1)
lenvatinib (4) · Immune Checkpoint Inhibitors (3) · atezolizumab (3) · Bevacizumab (2) · Glutamyl Aminopeptidase (2) · Observation (2) · Sorafenib (2) · apatinib (2) · camrelizumab (2) · donafenib (2) · regorafenib (2) · sintilimab (2) · spartalizumab (2) · Capecitabine (1) · Cisplatin (1)
China (30)
Ze-yang Ding, M.D. (3) · Bixiang Zhang (1) · Feng Shen, MD PhD (1) · Haitao Zhao, MD (1) · Hong Zhang, MD (1) · Jie Li, MD (1) · Jinhua Zhou (1) · Kang Shao, MD (1) · Ming He, MD (1) · Qiang Zeng, MD (1) · Shaohua Ma, M.D. (1) · Shun Lu, MD (1) · Wan-guang Zhang, M.D. (1)
PMID 17704786, PMID 24553385, PMID 25538264, PMID 25754329, PMID 25838375, PMID 25891174, PMID 26412456, PMID 27384348, PMID 27570942, PMID 28055103, PMID 28233802, PMID 28329770, PMID 28445469, PMID 28678778, PMID 28899864, PMID 33188140